Mayabeque, Cuba: Since the beginning of the COVID-19 epidemic in Cuba, health authorities directed the administration of Biomodulin T due to the vulnerability of the elderly to infection by SARS-CoV-2, reports Cubasí.
The Head of the Clinical Trials Group of the National Center for Bio-preparations, Dr. Mary Carmen Reyes Zamora, said that Biomodulin T is an immunomodulator, not a vaccine.
Reyes Zamora added that it is an extract of Thymus, an organ where differences are generated in T lymphocytes, cells in charge of the immune system that are very important in defense against infections and specifically viral ones.
The head of Clinical Trials at BIOCEN, located in Mayabeque, highlighted that they identified that older adults presented factors such as immunosenescence, underlying chronic diseases or comorbidities, close contact with their caregivers and varying degrees of dependence.
Therefore, she stated, it was decided to use Biomodulin T from the early stages in nursing homes, psycho-pedagogical medical centers, psychiatric hospitals and social protection centers with very positive results.
We were until the first five months of the pandemic without registering cases of older adults who had received treatment with Biomodulin T, the specialist stressed.
Among the most encouraging results, she noted that the probability of dying from COVID-19 is seven times lower if older adults received treatment with Biomodulin T and a sustained decrease in respiratory infections in this group.
